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Abstract 
A significant challenge in Glioblastoma (GBM) management is identifying pseudo-progression 
(PsP), a benign radiation-induced effect, from tumor recurrence, on routine imaging following 
conventional treatment. Previous studies have linked tumor lobar presence and laterality to GBM 
outcomes, suggesting that disease etiology and progression in GBM may be impacted by tumor 
location. Hence, in this feasibility study, we seek to investigate the following question: Can tumor 
location on treatment-naïve MRI provide early cues regarding likelihood of a patient developing 
pseudo-progression versus tumor recurrence? In this study, 74 pre-treatment Glioblastoma MRI 
scans with PsP (33) and tumor recurrence (41) were analyzed. First, enhancing lesion on Gd-T1w 
MRI and peri-lesional hyperintensities on T2w/FLAIR were segmented by experts and then 
registered to a brain atlas. Using patients from the two phenotypes, we construct two atlases by 
quantifying frequency of occurrence of enhancing lesion and peri-lesion hyperintensities, by 
averaging voxel intensities across the population. Analysis of differential involvement was then 
performed to compute voxel-wise significant differences (p-value<0.05) across the atlases. 
Statistically significant clusters were finally mapped to a structural atlas to provide anatomic 
localization of their location. Our results demonstrate that patients with tumor recurrence showed 
prominence of their initial tumor in the parietal lobe, while patients with PsP showed a multi-focal 
distribution of the initial tumor in the frontal and temporal lobes, insula, and putamen. These 
preliminary results suggest that lateralization of pre-treatment lesions towards certain anatomical 
areas of the brain may allow to provide early cues regarding assessing likelihood of occurrence of 
pseudo-progression from tumor recurrence on MRI scans.   
1 Introduction 
A significant challenge in management of Glioblastoma (GBM), the most aggressive form of brain 
cancer, is differentiating tumor recurrences from pseudo-progression (PsP) on routine magnetic 
resonance (MR) scans [1]. PsP is a benign radiation-induced treatment effect which occurs in 
approximately 19 – 33% of all malignant brain tumors [2] and usually stabilizes or regresses 
without further treatment. Unfortunately, PsP mimics tumor recurrence radiologically on routine 
MRI scans (Gadolinium-enhanced T1-weighted (Gd-T1w), T2-weighted (T2w), FLAIR), making 
it challenging to differentiate from true tumor recurrence [2]. Studies have previously explored 
advanced imaging modalities such as perfusion imaging [3 - 5], MR spectroscopy [4], and 
diffusion-weighted imaging [5] in distinguishing tumor recurrence from PsP. However, these 
advanced imaging modalities are limited by acquisition variability, costs, reproducibility, and 
unavailability at most clinical sites [6]. Reliable disease assessment using routine imaging is thus 
needed in order to aid in accurately identifying PsP from tumor recurrence. Timely identification 
of these conditions could avoid unnecessary interventions in patients with PsP, while allowing for 
change in treatment for patients with tumor recurrence [1]. 
Multiple studies have linked initial lesion location in the brain to be a prognostic marker of tumor 
recurrence and overall survival in diffuse Gliomas [7]. For instance, recent studies have 
demonstrated a higher rate of 1p19q deletion in the frontal lobe [8], and absence of 1DH1 mutation 
within the insula [9]. Similarly, Gliomas in the frontal locations have been shown to be associated 
with a better prognosis compared to other locations [10]. Further, enhancing lesion developing in 
the periventricular region has been linked to PsP [11, 12]. These studies seem to suggest that the 
underlying disease etiology may be driven by tumor location.  Hence, it may be reasonable to 
rationalize that initial GBM location in the brain may implicitly contribute to an increased 
likelihood of a patient developing pseudo-progression or tumor recurrence, following conventional 
treatment of maximal surgical resection and chemo-radiation therapy.  
In this feasibility study, we evaluate this hypothesis that lesion location on pre-treatment MR scans 
could provide early cues regarding likelihood of a patient developing tumor recurrences versus 
PsP. In order to anatomically localize the disease, we employ “population atlases” of GBM 
phenotypes to establish predisposition of tumor recurrence or PsP to specific spatial locations in 
the brain based on their frequency of occurrence [7, 13, 14]. The statistical population atlases allow 
for the succinct encapsulation of structural and anatomical variability of the disease across a patient 
population using a single reference or canonical representation. We will construct population 
atlases on a cohort of 74 brain MRI scans across two lesion sub-compartments (peritumoral 
hyperintensities as defined on FLAIR scans and enhancing core as defined on T1w MRI), to 
quantify the frequency of occurrence of PsP and tumor recurrence in pre-treatment lesions.  We 
will further employ a statistical mapping technique, ADIFFI, to identify if there exist any 
statistically significant lesion locations in the brain across the two disease pathologies, by 
comparing the population atlases of PsP and tumor recurrence.  
2 Materials and Methods 
2.1 Study Population 
The Institutional Review Board-approved and HIPAA-compliant study comprised GBM patient 
population from Cleveland Clinic. The population cohort for pre-treatment cases included 74 cases 
in total; 41 tumor recurrence cases, and 33 PsP cases. The studies were identified by performing a 
retrospective review of all brain tumor patients who received chemo-radiation treatment using the 
Stupp protocol at the respective institutions and had a suspected enhancing lesion within 3 months 
of treatment.  All cases were confirmed for disease presence using the criteria provided below. 
Informed consent was obtained for all patients involved in the study. All MR scans were acquired 
using either a 1.5 Tesla or a 3-Tesla scanner. Table 1 summarizes the demographics for this study 
population. 
2.2 Confirmation for disease presence 
Our inclusion criteria consisted of the following: (1) pre-, and post-treatment MRI scans that are 
of diagnostic image quality as determined by collaborating radiologists, (2) availability of all 3 
routine MRI sequences (Gd-T1w, T2w, FLAIR), (3) a suspected post-treatment enhancing lesion 
with more than 5 millimeters (mm) of rim or nodular enhancement, and (4) confirmation of PsP 
or tumor recurrence for the suspected lesion, obtained using RANO criteria [15] on follow-up MRI 
scans.   
2.3 Image Registration and Tumor segmentation  
Every pre-treatment MRI lesion was annotated into 2 regions: enhancing lesion and T2w/FLAIR 
hyperintense peri-lesional component. Gd-T1w MRI scans were used to delineate the enhancing 
lesion, while both T2w and FLAIR scans were used to annotate the T2w/FLAIR hyperintense peri-
lesional compartment. All annotations were performed by two experienced readers via an open 
source hand-annotation tool in 3D Slicer [16].  
In order to map all scans to the same space for the purpose of spatial atlas construction, the 3 MRI 
sequences for each patient, Gd-T1w MRI, T2w, and FLAIR, were co-registered to a 1.0-mm 
isotropic T1-weighted brain atlas (MNI152; Montreal Neurological Institute) using mutual 
information with 12-degrees of freedom. This was followed by visual inspection to make sure all 
images were properly aligned. Skull stripping was then performed using a deformable surface 
classification algorithm [17], followed by bias field correction that was performed using the 
nonparametric non-uniform intensity normalization technique in [18]. 
2.4 Frequency Map Construction 
From the available annotations for both enhancing lesion and T2w/FLAIR hyperintense peri-
lesional compartments, population atlases for each compartment were built for both pathologies 
(tumor recurrence and PsP). These atlases were constructed to quantify the frequency of 
occurrence of both enhancing lesion and peri-lesional hyperintensities across tumor recurrence and 
PsP, by averaging intensity values for all voxels across all the annotated binary images of all 
patients involved in the study.  The frequency of lesion occurrence was visualized using a heat 
map superimposed on the reference MNI152 atlas.  
2.5 Analysis of Differential Involvement (ADDIFI) 
From the constructed tumor progression and PsP frequency atlases, analysis of differential 
involvement (ADIFFI) was performed as described in [7], once for the enhancing lesion 
compartment and once for the peri-lesional hyperintensities. First, a two-tailed Fisher’s exact test 
was conducted, to evaluate a 2x2 contingency table that compares tumor recurrence/PsP along 
with tumor/non-tumor occurrence for each voxel across all patients. From this voxel-wise analysis, 
significance level was then measured, and the voxels that yielded p-value<0.05 were stored.  The 
voxel-wise probabilities according to Fisher’s exact test are computed using the following formula: 
𝒑 =
(𝒂 + 𝒃)! (𝒄 + 𝒅)! (𝒂 + 𝒄)! (𝒃 + 𝒅)!
𝒂! 𝒃! 𝒄! 𝒅! 𝒏!
, 
where 𝑎, 𝑏, 𝑐, 𝑑, and 𝑛 are defined as follows: 
𝑎:  represents the number of tumor recurrence as well as the lesion-positive occurrences across 
all subjects at the current voxel. 
𝑏: represents the number of tumor progression as well as the lesion-negative occurrences across 
all subjects at the current voxel. 
𝑐: represents the number of PsP as well as the lesion-positive occurrences across all subjects at 
the current voxel. 
𝑑: represents the number of PsP as well as the lesion-negative occurrences across all subjects at 
the current voxel.   
𝑛: represents the total number of studies.  
Next, connected component analysis was applied, [19], to cluster all statistically significant voxels 
found across the two compartments for both tumor recurrence and PsP that appeared on the 
ADIFFI maps, for enhancing lesion as well as for peri-lesional hyperintensities. The brain was 
finally partitioned using pre-labeled anatomical structures in MNI space [20], for the purpose of 
identifying the anatomic areas of localization for tumor recurrence/PsP across all subjects.  
2.6 Cluster-size correction using random permutation analysis 
Due to the extensive number of voxel-wise calculations performed during ADIFFI, multiple 
comparison corrections were performed. For this task, random permutation (RP) analysis was 
conducted for cluster size correction [21]. Specifically, all T2w/FLAIR hyperintense peri-lesional 
components, as well as the enhancing lesion ones, across the two categories (tumor recurrence/ 
PsP) were randomly reassigned to one of these pathologies, then ADIFFI was re-conducted, and 
voxels with p-values less than 0.05 were stored. In addition, the sizes of statistically significant 
clusters were documented. The whole process was reiterated for 500 times. RP analysis was 
employed in order to identify distinct clusters occurring less than 5% by chance, which would 
provide distinct spatial differences between tumor recurrence and PsP.  
Finally, statistically significant clusters appearing on the cluster-size corrected ADIFFI maps were 
designated as either PsP or tumor recurrence by referring to the population atlases that were 
individually constructed for tumor recurrence and PsP. A specific anatomic localization was then 
obtained from these cluster-size corrected ADIFFI maps, by mapping them to a structural MNI 
atlas. The entire pipeline of this work is shown in Figure [1]. 
3 Results 
The resulting frequency maps that were constructed for both T2w/FLAIR hyperintense peri-
lesional and lesion areas from pre-treatment scans are shown in Figures [2], [3] respectively. These 
figures show that tumor recurrence in both compartments (enhancing lesion and T2w/FLAIR 
hyperintense peri-lesional areas) is more likely lateralized towards the parietal lobe, whereas PsP 
is more likely to be multi-focally distributed across different anatomical areas of the brain 
including frontal and temporal lobes, the insula, and the putamen. 
3.1 Tumor recurrence is lateralized towards the parietal lobe 
  
The frequency maps as well as ADIFFI maps for peri-lesional T2/FLAIR hyperintensities of the 
pre-treatment scans show that tumor recurrence is more likely to be present in the parietal lobe, 
with frequency of occurrence of 85%, Fig [2 a], Fig [4 a]. About 59% of this distribution was 
found in the right hemisphere, whereas 41% was found in the left hemisphere. Frequency maps as 
well as ADIFFI maps obtained for the enhancing lesion also reveal that tumor recurrence is more 
likely to be present in the parietal lobe of left and right hemispheres (70% and 30% chances of 
occurrence respectively), Fig [3 a], Fig [4 c]. These results suggest that tumor recurrence exhibits 
lobar prominence across the population atlases, but do not exhibit any hemisphere-specific 
preference. 
3.2 Pseudo-progression exhibits a multi-focal distribution in the enhancing lesion as well as 
the perilesional hyperintensities 
PsP, unlike tumor recurrence, seems to more likely be multi-focally distributed across the brain in 
pre-treatment cases, for both the enhancing lesion and the peri-lesional hyperintensities. PsP 
exhibited a multi-focal distribution in the right hemisphere of the peri-lesional hyperintensities, 
with frequencies of occurrence of 55% in the frontal lobe, 11% in the temporal lobe, 10% in the 
insula, and 10% in the putamen (Fig [2 b], Fig [4 b]). In the analysis of the enhancing lesion 
regions, PsP appears to more likely be multi-focally distributed within both left and right 
hemispheres. The spatial distribution was 35% in the insula (with 63% of this distribution in the 
right hemisphere and 37% in the left hemisphere), 21% in the right frontal lobe, 13% in the right 
temporal lobe, and 17% in the putamen (with 57% of this distribution in the right hemisphere and 
43% in the left hemisphere), Fig [3 b], Fig [4 d]. 
3.3 Random permutation analysis for cluster size correction 
RP analysis conducted on the peri-lesional T2/FLAIR hyperintensities of the pre-treatment cases 
revealed that the average and standard deviation of maximum cluster size are 3700 and 1726.8 
voxels respectively. Also, 95% of the cluster sizes were smaller than 6192 voxels, meaning that 
clusters larger than this size threshold would occur in less than 5% of all random permutations. 
This resulted in one distinct T2w/FLAIR hyperintense peri-lesional cluster size of 6502 voxels, 
localized at the right parietal lobe, and associated with tumor recurrence, and another one of size 
of 6200 voxels localized at the left parietal lobe. 
RP analysis conducted on the enhancing lesion revealed that average and standard deviation of 
maximum cluster size are 2258 and 1774.1 voxels respectively. Also, 95% of the cluster sizes were 
smaller than 5164 voxels, meaning that clusters larger than this size threshold would occur in less 
than 5% of all random permutations. This resulted in one distinct enhancing lesion cluster size of 
5450 voxels, localized at the left parietal lobe, and associated with tumor recurrence. 
The designation of PsP or true progression based on ADIFFI maps as for each significant 
voxel/cluster was accomplished by referring to the population atlases of both compartments 
(enhancing lesion, T2w/FLAIR hyperintense peri-lesion) that were individually constructed for 
tumor recurrence and PsP. The cluster-size corrected ADIFFI maps obtained for tumor recurrence 
are shown in Fig [1 d].  
The extent of resection (available for n=37 subjects), age, and gender were not found to be 
independently prognostic of presence of PsP versus tumor recurrence. 
4 Discussion  
Distinguishing tumor recurrence from PsP is one of the biggest clinical challenges in GBM 
management. This feasibility study aimed at creating population atlases to study spatial proclivity 
of brain tumor recurrence versus PsP based on their occurrences on pre-treatment MR scans. The 
study assessed the voxel-wise tumor frequency across two lesion compartments using a statistical 
mapping technique named ADIFFI, in efforts to find significant spatial distribution differences 
between the two phenotypes. 
Our preliminary findings suggest that likelihood of tumor recurrence is more consistent with 
lesions occurring in the parietal lobe of both left and right hemispheres, based on the analysis of 
both enhancing lesion and peri-lesional T2/FLAIR hyperintensities, on pre-treatment MRI scans.  
Parietal lobe is largely responsible for cognitive functions. Damage to parietal lobe may have direct 
implications in processing speech as well as sensory information.  Hence, presence of tumor 
recurrence in parietal lobe may cause symptoms associated with numbness and tingling, hemi-
neglect, and cognitive issues around right-left confusion and reading and math problems. PsP, on 
the other hand, did not exhibit lobar-specific distribution in pre-treatment scans, but showed a 
multi-focal distribution of the initial tumor in the frontal (associated with motor function, memory, 
problem solving) and temporal lobes (associated with primary auditory perception, such as hearing 
and visual recognition) as well as the insula and putamen.  While the association of presence of 
tumor recurrence or PsP with specific lobes in the brain is not well-understood, their presence in 
specific lobes could ultimately contribute towards making more informed decisions regarding their 
diagnosis.  
Previous studies have largely employed population atlases in brain tumors using pre-treatment 
MRI to obtain probabilistic maps of spatial predisposition in patients based on their disease 
aggressiveness [22] or molecular status [7, 23, 24]. For instance, a few studies have shown that 
tumor recurrence closer to the ventricular system was significantly associated with poor survival 
[25, 26]. Interestingly, the study in [27] showed that tumors in the right occipito-temporal 
periventricular white matter were significantly associated with poor survival in both training and 
test cohorts.  Similarly, more aggressive GBMs were reported to be close to the ventricular system, 
and had a rapid progression [28], suggesting that tumor location may play a significant role in 
disease etiology.  
The closest studies to our work have attempted to identify associations of lesion location with 
likelihood of tumor recurrence and PsP, to investigate any spatial differences between the two 
phenotypes. For instance, the study by Tsien et al. [29] incorporated location along with clinical 
and conventional MRI parameters to distinguish tumor progression from PsP in high-grade 
gliomas, yet no significant location differences could be found between the two groups, perhaps 
on account of the relatively small population size involved in this study (27 patients total). The 
study by Van West et al [11] reported the incidence of PsP in low grade gliomas, and found that 
50% of their PsP enhancing lesions were located in the periventricular walls; attributing to the 
relatively poor blood supply in the periventricular areas that make it more vulnerable to radiation-
induced processes. However, these studies did not report any findings regarding lobular 
preferences for either PsP or tumor recurrence in GBMs.  
Our study did have its limitations. While our results are promising as a feasibility study, the study 
did not consider the molecular status (i.e. MGMT), or Karnofsky performance score as potential 
confounders during analysis. While the extent of resection on a limited subset of studies was not 
found to be independently prognostic of tumor recurrence, these findings need to be validated on 
a larger multi-institutional cohort. The prognostic implications (i.e. predicting patient overall 
survival), based on the location differences across PsP and tumor recurrence were not studied as a 
part of the current work, and will be investigated in the future.  
To conclude, this study attempted to demonstrate the likelihood of occurrence of tumor recurrence 
and pseudo-progression, using the location of the lesion on pre-treatment MR scans. Our results 
revealed distinct localization between tumor recurrences and PsP that could aid in predicting these 
two similar appearing pathological conditions. Future work will focus on integrating the location 
biomarker with other biomarkers, such as shape and texture features, on a larger cohort of multi-
institutional studies. We will also consider identifying location specific markers associated with 
radiation necrosis (delayed treatment effects) versus tumor recurrence. 
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Figures 
 
Figure 1: Pipeline of the framework. (a) MR scans of tumor recurrence and pseudo-progression. 
(b) Frequency map atlases that were constructed from the two classes. (c) Results from Fisher’s 
Exact test on peri-lesional T2/FLAIR hyperintensities in tumor recurrence (Top), and enhancing 
lesion in tumor recurrence (Bottom). (d) Results after applying RP analysis on ADIFFI maps 
shown in (c). 
 Figure 2: (a) Frequency maps of tumor occurrence for peri-lesional T2/FLAIR hyperintensities in 
tumor recurrence of pre-treatment scans, where lobar prominence is present in the parietal lobe of 
both hemispheres. (b) Frequency maps of tumor occurrence for peri-lesional T2/FLAIR 
hyperintensities in pseudo-progression, where a multi-focal distribution is present in the frontal 
lobe, temporal lobe, insula, and putamen of the right hemisphere. 
 
Figure 3: (a) Frequency maps of tumor occurrence for enhancing lesion in tumor recurrence of 
pre-treatment scans, where lobar prominence is present in the parietal lobe of both hemispheres. 
(b) Frequency maps of tumor occurrence for enhancing lesion in pseudo-progression, where a 
multi-focal distribution is present in the insula, frontal lobe, putamen, and the temporal lobe, of 
both left and right hemispheres. 
 Figure 4: (a) ADIFFI maps for peri-lesional T2/FLAIR hyperintensities in tumor recurrence, and 
(b) pseudo-progression. (c) ADIFFI maps for enhancing lesion in tumor recurrence, and (d) 
pseudo-progression. The level of significance was at a P-value of 0.05 for all of these maps. These 
were the maps prior to applying RP analysis. (e) The labeled anatomical MNI atlas that is used for 
parcellating ADIFFI maps and identifying significant areas. 
Tables 
Characteristic Tumor Recurrence Pseudo-progression 
No. of patients 41 33 
Females 16 12 
Males 25 21 
Mean age (year) 59.1 61.96 
Age range (year) 26 - 75 24 - 75 
Table 1: Summary of the study population used in this work to create population atlases for PsP 
and tumor recurrence. 
  
